Project 3 -- MIDUS Biomarker Project

摘要-生物标记物项目 生物标记物项目在MIDUS努力将老龄化理解为一个综合的 生物心理社会过程。我们之前的生物标志物数据得到了科学界的广泛参与 社区：产生了403份出版物，其中162份是2019年以来出版的。未来的目标是 是通过收集关于刷新器子样本(n=647)的第二波纵向数据来建立该动量， 以及关于核心子样本的第四波纵向数据(n=630)，总预测N=1,277。我们会 重复我们全面的生物标志物(神经内分泌、炎症、葡萄糖代谢、 心血管、肌肉骨骼)Plus增加了与阿尔茨海默病相关的新措施 痴呆，包括淀粉样β蛋白(Aβ40，Aβ42)，神经丝光(NFL)，P-tau，以及 慢性炎症的新指标(SuPAR)。我们还将添加蒙特利尔认知评估(MoCA) 还有听力测试。我们将调查关于社会经济和心理社会影响的假说。 对随后的生物学变化的不利影响，预测那些暴露在更大累积逆境中的人 随着时间的推移，会表现出更高的生物风险和更大的功能损害。我们还将调查 心理社会资源在缓解(减轻)人类健康不良后果中的作用 社会经济和种族差距。我们将利用MIDUS设计，涉及两个国家样本(核心、 Realher)及时展开，以检查#年健康结果中不断扩大的社会经济地位差异 不同历史时期的同龄群体。这些分析将包括压力暴露。 与大衰退有关(此前评估)和新冠肺炎的新评估艰辛 大流行。相比之下，MIDUS Biomarker项目有三个关键特征与美国其他项目不同。 学习。首先，它将在核心国家样本中提供20年来的3波生物数据和2波 在更新的国家样本中，对10年来的生物数据进行了分析，所有这些数据都是以中年成年人为基准获得的。 其次，在MIDUS收集的生物标记物比任何其他基于美国人口的样本都要丰富得多。第三, MIDUS的广泛调查数据-包括数十年的社会经济预期信息， 参与者生活的心理、社会和行为方面--提供了独特的机会来测试这些 各种因素综合在一起，说明了谁保持了健康的生物调节和功能健康 时间，而其他人已经转移到临床上重要的生物风险，或从疾病前转移到疾病 各州。MIDUS生物标记物措施也在其他项目(《调查》、《每日》、 基因组学)这一U19应用以及组件(认知、情感神经科学、ADRD 神经科学)的辅助U01应用。

ABSTRACT – BIOMARKER PROJECT The Biomarker Project plays a central role in the MIDUS efforts to understand aging as an integrated biopsychosocial process. Our prior biomarker data have received widespread engagement from the scientific community: 403 publications have been generated, 162 of which appeared since 2019. The goal going forward is to build on this momentum by collecting a 2nd wave of longitudinal data on the Refresher subsample (n=647), and a 4th wave of longitudinal data on the Core subsamples (n=630), for a total projected N=1,277. We will repeat our comprehensive battery of biomarkers (neuroendocrine, inflammatory, glucose metabolism, cardiovascular, musculoskeletal) plus add new measures related to Alzheimer’s Disease and Related Dementias (ADRD), including amyloid beta (Aβ40, Aβ42), neurofilament light (NFL), and P-tau, along with a new measure of chronic inflammation (suPAR). We will also add the Montreal Cognitive Assessment (MoCA) and a hearing test. We will investigate hypotheses about the effects of socioeconomic and psychosocial disadvantage on subsequent change in biology, predicting that those exposed to greater cumulative adversity will show heightened biological risk over time and greater functional impairment. We will also investigate the role of psychosocial resources in moderating (mitigating) against the adverse health consequences of socioeconomic and racial disparities. We will exploit the MIDUS design involving two national samples (Core, Refresher) unfolding in time to examine widening socioeconomic status differential in health outcomes in same-aged groups across different historical periods. Included in these analyses will be stress exposures related to the Great Recession (previously assessed) and newly assessed hardships of the COVID-19 pandemic. Viewed comparatively, three key features distinguish the MIDUS Biomarker Project from other U.S. studies. First, it will provide 3 waves of biological data over 20 years in the Core national sample and 2 waves of biological data over 10 years in the Refresher national sample, all obtained on mid-life adults at baseline. Second, the biomarkers collected in MIDUS are far richer than any other U.S. population-based sample. Third, the extensive survey data of MIDUS – encompassing decades of prospective information on socioeconomic, psychosocial, and behavioral aspects of participants’ lives -- provide unique opportunities for testing how these factors combine to account for who has maintained healthy biological regulation and functional health across time, while others have shifted toward clinically significant biological risk, or moved from pre-disease to disease states. The MIDUS biomarker measures are also prominently featured in other projects (Survey, Daily, Genomics) of this U19 application as well as the components (Cognitive, Affective Neuroscience, ADRD Neuroscience) of the Ancillary U01 application.